TherapeuticsMD, Inc. Cost of Revenue
TherapeuticsMD, Inc. (TXMD) reported Cost of Revenue of $1.40 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2024-03-29
- TherapeuticsMD, Inc. cost of goods and services sold for the quarter ending 2022-12-31 was $0.00.
- TherapeuticsMD, Inc. cost of goods and services sold for the quarter ending 2022-09-30 was $354.00K, a 93.30% decline year-over-year.
- TherapeuticsMD, Inc. cost of goods and services sold for the quarter ending 2022-06-30 was $348.00K, a 91.58% decline year-over-year.
- TherapeuticsMD, Inc. cost of goods and services sold for the quarter ending 2022-03-31 was $695.00K, a 85.17% decline year-over-year.
- TherapeuticsMD, Inc. cost of goods and services sold for fiscal 2022 was $1.40M, a 0.36% decline from fiscal 2021.
- TherapeuticsMD, Inc. cost of goods and services sold for fiscal 2021 was $1.40M, a 91.22% decline from fiscal 2020.
- TherapeuticsMD, Inc. cost of goods and services sold for fiscal 2020 was $15.97M, a 152.17% increase from fiscal 2019.
- TherapeuticsMD, Inc. cost of goods and services sold for fiscal 2019 was $6.33M, a 131.40% increase from fiscal 2018.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $354.00K derived: sum of 2 quarters · filed 2024-03-29 | $702.00K derived: sum of 3 quarters · filed 2024-03-29 | $1.40M 10-K · filed 2024-03-29 | ||||
| 2022-09-30 | $354.00K 10-Q · filed 2023-11-14 | $3.79M 10-Q · filed 2022-11-14 | $702.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.40M 10-Q · filed 2023-11-14 | $13.39M 10-Q · filed 2022-11-14 | -$11.30M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $348.00K 10-Q · filed 2023-08-14 | $4.74M 10-Q · filed 2022-08-15 | $1.04M 10-Q · filed 2023-08-14 | $9.60M 10-Q · filed 2022-08-15 | -$11.66M derived: sum of 3 quarters · filed 2023-08-14 | -$6.37M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $695.00K 10-Q · filed 2023-05-15 | $4.86M 10-Q · filed 2022-05-16 | -$12.00M derived: sum of 2 quarters · filed 2023-05-15 | -$6.72M derived: sum of 3 quarters · filed 2023-05-15 | -$2.59M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$12.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-07 | -$7.42M derived: sum of 2 quarters · filed 2023-04-07 | -$3.29M derived: sum of 3 quarters · filed 2023-04-07 | $1.40M 10-K · filed 2023-04-07 | $18.84M 10-K · filed 2022-03-23 | |||
| 2021-09-30 | $5.28M 10-Q · filed 2022-11-14 | $9.41M derived: sum of 2 quarters · filed 2022-11-14 | $14.10M 10-Q · filed 2022-11-14 | $19.68M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $4.13M 10-Q · filed 2022-08-15 | $8.82M 10-Q · filed 2022-08-15 | $14.40M derived: sum of 3 quarters · filed 2022-08-15 | $17.68M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | $4.69M 10-Q · filed 2022-05-16 | $10.27M derived: sum of 2 quarters · filed 2022-05-16 | $13.55M derived: sum of 3 quarters · filed 2022-05-16 | $17.95M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $5.58M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $8.86M derived: sum of 2 quarters · filed 2022-03-23 | $13.26M derived: sum of 3 quarters · filed 2022-03-23 | $15.97M 10-K · filed 2022-03-23 | $15.97M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $3.28M 10-Q · filed 2021-11-12 | $3.28M 10-Q · filed 2020-11-09 | $7.68M derived: sum of 2 quarters · filed 2021-11-12 | $10.39M 10-Q · filed 2021-11-12 | $10.39M 10-Q · filed 2020-11-09 | $13.27M derived: sum of 4 quarters · filed 2022-03-23 | ||
| 2020-06-30 | $4.40M 10-Q · filed 2021-08-04 | $4.40M 10-Q · filed 2020-08-07 | $7.12M 10-Q · filed 2021-08-04 | $7.12M 10-Q · filed 2020-08-07 | $9.99M derived: sum of 3 quarters · filed 2022-03-23 | $11.44M derived: sum of 4 quarters · filed 2022-03-23 | ||
| 2020-03-31 | $2.71M 10-Q · filed 2021-05-06 | $2.72M 10-Q · filed 2020-05-06 | $5.59M derived: sum of 2 quarters · filed 2022-03-23 | $7.04M derived: sum of 3 quarters · filed 2022-03-23 | $8.29M derived: sum of 4 quarters · filed 2022-03-23 | |||
| 2019-12-31 | $2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $4.32M derived: sum of 2 quarters · filed 2022-03-23 | $5.57M derived: sum of 3 quarters · filed 2022-03-23 | $6.33M 10-K · filed 2022-03-23 | $6.33M 10-K · filed 2020-02-24 | |||
| 2019-09-30 | $1.44M 10-Q · filed 2020-11-09 | $2.69M derived: sum of 2 quarters · filed 2020-11-09 | $3.46M 10-Q · filed 2020-11-09 | $4.41M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-06-30 | $1.25M 10-Q · filed 2020-08-07 | $2.01M 10-Q · filed 2020-08-07 | $2.96M derived: sum of 3 quarters · filed 2021-03-04 | $3.66M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2019-03-31 | $762.83K 10-Q · filed 2020-05-06 | $1.71M derived: sum of 2 quarters · filed 2021-03-04 | $2.41M derived: sum of 3 quarters · filed 2021-03-04 | $2.87M derived: sum of 4 quarters · filed 2021-03-04 | ||||
| 2018-12-31 | $950.75K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.65M derived: sum of 2 quarters · filed 2021-03-04 | $2.10M derived: sum of 3 quarters · filed 2021-03-04 | $2.74M 10-K · filed 2021-03-04 | ||||
| 2018-09-30 | $699.12K 10-Q · filed 2019-11-08 | $1.15M derived: sum of 2 quarters · filed 2019-11-08 | $1.79M 10-Q · filed 2019-11-08 | $2.38M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-06-30 | $454.16K 10-Q · filed 2019-08-09 | $1.09M 10-Q · filed 2019-08-09 | $1.68M derived: sum of 3 quarters · filed 2020-02-24 | $2.38M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2018-03-31 | $633.62K 10-Q · filed 2019-05-08 | $1.23M derived: sum of 2 quarters · filed 2020-02-24 | $1.93M derived: sum of 3 quarters · filed 2020-02-24 | $2.61M derived: sum of 4 quarters · filed 2020-02-24 | ||||
| 2017-12-31 | $594.77K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-24 | $1.30M derived: sum of 2 quarters · filed 2020-02-24 | $1.98M derived: sum of 3 quarters · filed 2020-02-24 | $2.64M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | $700.81K 10-Q · filed 2018-11-08 | $1.38M derived: sum of 2 quarters · filed 2018-11-08 | $2.04M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $681.73K 10-Q · filed 2018-07-30 | $1.34M 10-Q · filed 2018-07-30 | ||||||
| 2016-12-31 | $4.19M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |